Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPembroMel: Neoadjuvant Pembrolizumab for Melanoma
NCT02306850Phase 2Completed
- Sponsor
- Saint Louis University
- Start
- Jan 2015
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by Saint Louis University. Primary endpoint: Resectability Rate at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02306850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306850.